Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
We report on a case of metastatic urothelial bladder carcinoma (mUBC) treated with anlotinib combined with sintilimab. A 69-year-old male was diagnosed with non-muscle invasive bladder cancer (NMIBC). He received transurethral resection of bladder tumor (TURBT) and intravesical gemcitabine chemother...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.643413/full |
id |
doaj-e01bec14781d4beca69e3ffe3a88b5f8 |
---|---|
record_format |
Article |
spelling |
doaj-e01bec14781d4beca69e3ffe3a88b5f82021-05-24T05:21:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.643413643413Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 MutationJian-zhou Cao0Jian-zhou Cao1Wei Wu2Jin-feng Pan3Jin-feng Pan4Hong-wei Wang5Jun-hui Jiang6Jun-hui Jiang7Qi Ma8Qi Ma9Qi Ma10Qi Ma11Medical School, Ningbo University, Ningbo, ChinaComprehensive Urogenital Cancer Center, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, ChinaDepartment of Medical Oncology, Mingzhou Hospital, Ningbo, ChinaMedical School, Ningbo University, Ningbo, ChinaComprehensive Urogenital Cancer Center, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, ChinaDepartment of Pathology, People’s Hospital, The Affiliated Hospital of Ningbo University, Ningbo, ChinaDepartment of Urology, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, ChinaNingbo Clinical Research Center for Urological Disease, Ningbo, ChinaComprehensive Urogenital Cancer Center, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, ChinaDepartment of Urology, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, ChinaNingbo Clinical Research Center for Urological Disease, Ningbo, ChinaTranslational Research Laboratory for Urology, The Key Laboratory of Ningbo City, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, ChinaWe report on a case of metastatic urothelial bladder carcinoma (mUBC) treated with anlotinib combined with sintilimab. A 69-year-old male was diagnosed with non-muscle invasive bladder cancer (NMIBC). He received transurethral resection of bladder tumor (TURBT) and intravesical gemcitabine chemotherapy. After the patients’ cancer progressed to mUBC, cisplatin-based chemotherapy (gemcitabine combined with cisplatin, GC) was performed to this patient as first line therapy for four cycles. However, the disease progressed again within 6 months. Local radiotherapy was performed on the metastatic lesions, and after radiotherapy, the patient received anti-PD-1 antibody (sintilimab 200 mg, q3w)combined with Albumin-bound (Nab)-paclitaxel (100 mg, qw) as the second-line therapy, but the patient’s cancer was still observed to be progressing. Molecular characterization confirmed the presence of FGFR3 mutations in the patient. Anlotinib was recommended to this patient. After the patient was fully informed and he was aware of off-label use of the drug, then, Nab-paclitaxel was replaced by anlotinib (10 mg D1–14, q3w) and sintilimab infusions were maintained for every 3 weeks. Partial response (PR) was observed through imaging examinations and stable disease (SD) was observed for more than 11 months; the patient’s quality of life also improved. This case suggested that anlotinib combined with sintilimab may be a safe and effective choice in the treatment of mUBC in patients with FGFR3 mutations.https://www.frontiersin.org/articles/10.3389/fonc.2021.643413/fullanlotinibsintilimabimmunotherapytargeted therapymetastatic urothelial bladder carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jian-zhou Cao Jian-zhou Cao Wei Wu Jin-feng Pan Jin-feng Pan Hong-wei Wang Jun-hui Jiang Jun-hui Jiang Qi Ma Qi Ma Qi Ma Qi Ma |
spellingShingle |
Jian-zhou Cao Jian-zhou Cao Wei Wu Jin-feng Pan Jin-feng Pan Hong-wei Wang Jun-hui Jiang Jun-hui Jiang Qi Ma Qi Ma Qi Ma Qi Ma Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation Frontiers in Oncology anlotinib sintilimab immunotherapy targeted therapy metastatic urothelial bladder carcinoma |
author_facet |
Jian-zhou Cao Jian-zhou Cao Wei Wu Jin-feng Pan Jin-feng Pan Hong-wei Wang Jun-hui Jiang Jun-hui Jiang Qi Ma Qi Ma Qi Ma Qi Ma |
author_sort |
Jian-zhou Cao |
title |
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation |
title_short |
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation |
title_full |
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation |
title_fullStr |
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation |
title_full_unstemmed |
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation |
title_sort |
case report: anlotinib combined with sintilimab as third-line treatment in a metastatic urothelial bladder carcinoma patient with fgfr3 mutation |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-05-01 |
description |
We report on a case of metastatic urothelial bladder carcinoma (mUBC) treated with anlotinib combined with sintilimab. A 69-year-old male was diagnosed with non-muscle invasive bladder cancer (NMIBC). He received transurethral resection of bladder tumor (TURBT) and intravesical gemcitabine chemotherapy. After the patients’ cancer progressed to mUBC, cisplatin-based chemotherapy (gemcitabine combined with cisplatin, GC) was performed to this patient as first line therapy for four cycles. However, the disease progressed again within 6 months. Local radiotherapy was performed on the metastatic lesions, and after radiotherapy, the patient received anti-PD-1 antibody (sintilimab 200 mg, q3w)combined with Albumin-bound (Nab)-paclitaxel (100 mg, qw) as the second-line therapy, but the patient’s cancer was still observed to be progressing. Molecular characterization confirmed the presence of FGFR3 mutations in the patient. Anlotinib was recommended to this patient. After the patient was fully informed and he was aware of off-label use of the drug, then, Nab-paclitaxel was replaced by anlotinib (10 mg D1–14, q3w) and sintilimab infusions were maintained for every 3 weeks. Partial response (PR) was observed through imaging examinations and stable disease (SD) was observed for more than 11 months; the patient’s quality of life also improved. This case suggested that anlotinib combined with sintilimab may be a safe and effective choice in the treatment of mUBC in patients with FGFR3 mutations. |
topic |
anlotinib sintilimab immunotherapy targeted therapy metastatic urothelial bladder carcinoma |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.643413/full |
work_keys_str_mv |
AT jianzhoucao casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT jianzhoucao casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT weiwu casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT jinfengpan casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT jinfengpan casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT hongweiwang casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT junhuijiang casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT junhuijiang casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT qima casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT qima casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT qima casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation AT qima casereportanlotinibcombinedwithsintilimabasthirdlinetreatmentinametastaticurothelialbladdercarcinomapatientwithfgfr3mutation |
_version_ |
1721428827804008448 |